Prescription Drugs - Research and Data from KFF

The Effect of Delaying the Selection of Small Molecule Drugs for Medicare Drug Price Negotiation

Apr 16, 2025

Policy Watch

In a new Trump administration executive order, the Secretary of HHS is directed to work with Congress to implement a change in law to delay negotiation of so-called “small molecule” drugs under the Inflation Reduction Act's Medicare Drug Price Negotiation Program for an additional 4 years. This brief analyzes how many of the drugs previously selected for negotiation would not have been eligible if this policy had been in place at the time.

Health Spending Issues to Watch This Year

Apr 10, 2025

Issue Brief

KFF and the Peterson Center on Healthcare examine market trends contributing to rising health costs and identify several potential federal and state policy issues to watch throughout 2025, including high-cost drugs, federal funding cuts, and workforce shortages.

Classifying Misoprostol and Mifepristone as Controlled Substances: Implications for the Management of Non-Abortion Related Conditions

Apr 3, 2025

Issue Brief

This data note analyzes employer-sponsored insurance and Medicaid claims data to see how mifepristone and misoprostol—two drugs used in the medication abortion regimen—are prescribed for reasons other than abortion including management of miscarriages, abnormal bleeding or hemorrhage, as well as IUD insertions and other conditions.

Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor

Feb 13, 2025

Feature

This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.

KFF Prescription Drug Advertisements Poll: January 2025

Feb 11, 2025

Poll Finding

KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public's experiences with prescription drug advertisements, whether they've talked to a doctor about advertised drugs, and how this has influenced the care they receive.

KFF Health Tracking Poll: Public Weighs Health Care Spending and Other Priorities for Incoming Administration

Jan 17, 2025

Feature

With the incoming Trump administration and Republican-led Congress looking to ways to reduce federal spending, this Poll finds that the Medicare and Medicaid programs remain broadly popular, and more people favor more spending on those programs than less spending. Among potential actions on health, the public sees price transparency and limiting chemicals in food as top priorities. Few say so about cuts to Medicaid and restrictions on abortion.

Ozempic’s Selection for Medicare Drug Price Negotiation Could Raise the Stakes for the Negotiation Program

Jan 17, 2025

Quick Take

Semaglutide…has been selected for the second round of Medicare drug price negotiation…Many people are familiar with Ozempic and other drugs like it, use of these drugs has expanded rapidly in recent years, and the list price is high. All of that could focus more attention on this year’s drug price negotiation process….

What’s Next for Medicare Negotiated Drug Prices Under the Trump Administration?

Jan 17, 2025

Quick Take

The Trump Administration could go in one of three directions with the Medicare negotiations program: stay the course, water it down or repeal it all together. There are potential tradeoffs with each, but the first would be most popular.

How Medicare Negotiated Drug Prices Compare to Other Countries

Dec 19, 2024

Issue Brief

This analysis finds that Medicare's negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.

Why Medicare Drug Price Negotiation Matters for Potential Medicare Coverage of Obesity Drugs

Dec 2, 2024

Quick Take

It’s quite likely that one of these popular anti-obesity medications will be selected for negotiation in the next round of Medicare’s relatively new drug price negotiation program.

Topics

Policy Research

Polling

Health News

Data & Features

For Media

About

View the Latest: Prescription Drugs

Filter